Pediatric Hematology and Oncology最新文献_第10页

Accuracy of online medical information: the case of social media in sickle cell disease. 在线医疗信息的准确性:镰状细胞病的社交媒体案例

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-03-01 DOI: 10.1080/08880018.2022.2075500

Nichole Slick, Prasad Bodas, Sherif M Badawy, Beth Wildman

{"title":"Accuracy of online medical information: the case of social media in sickle cell disease.","authors":"Nichole Slick, Prasad Bodas, Sherif M Badawy, Beth Wildman","doi":"10.1080/08880018.2022.2075500","DOIUrl":"https://doi.org/10.1080/08880018.2022.2075500","url":null,"abstract":"The medical needs of individuals with sickle cell disease (SCD) are complex. Patients with SCD experience complications such as recurrent pain episodes and increased hospitalizations. Over 70% of AYA and their parents seek medical information from the Internet; 83% inquire on sites that have interactive/social features, such as Facebook or Twitter, yet accuracy remains unclear. Our objective was to assess the accuracy of the SCD-information posted on social media. We hypothesized that most of the posted information is inaccurate. We coded one month of threads from two common SCD Facebook groups (Sickle Cell Warriors Unity and Sickle Cell Anemia) to identify the purpose of each post and the accuracy of medical information posted. Amongst both social media sites, there were 487 posts. Most of the posts were directed toward socializations (n = 311, 63.8%), while other posts mainly focused mainly on SCD and its management (n = 173, 35.5%). When looking at the medical posts, 44.9% were accurate, whereas 55.1% of the posts included inaccurate information. We found that less than half of the medical information posted on interactive social media is inaccurate. Our findings raise potentially serious implications for individuals with SCD and/or their caregivers who may rely on social media to gather more information about their or their child's disease. Our data highlight the importance of health care providers encouraging patients and parents to ask any questions they may have about SCD, given they may consult social media and Internet site that provide inaccurate information.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":"40 2","pages":"99-107"},"PeriodicalIF":1.7,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9208398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Incidence and Risk Factors of Venous Thromboembolism in Childhood Acute Lymphoblastic Leukaemia - a Population-Based Analysis of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. 儿童急性淋巴细胞白血病静脉血栓栓塞的发生率和危险因素——奥地利柏林-法兰克福-梅<e:1>斯特(BFM)研究组基于人群的分析

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-03-01 DOI: 10.1080/08880018.2022.2089791

Anna Gidl, Anna Füreder, Martin Benesch, Michael Dworzak, Gernot Engstler, Neil Jones, Gabriele Kropshofer, Ulrike Pötschger, Fiona Poyer, Melanie Tamesberger, Volker Witt, Georg Mann, Andishe Attarbaschi

{"title":"Incidence and Risk Factors of Venous Thromboembolism in Childhood Acute Lymphoblastic Leukaemia - a Population-Based Analysis of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group.","authors":"Anna Gidl, Anna Füreder, Martin Benesch, Michael Dworzak, Gernot Engstler, Neil Jones, Gabriele Kropshofer, Ulrike Pötschger, Fiona Poyer, Melanie Tamesberger, Volker Witt, Georg Mann, Andishe Attarbaschi","doi":"10.1080/08880018.2022.2089791","DOIUrl":"https://doi.org/10.1080/08880018.2022.2089791","url":null,"abstract":"Venous thromboembolism (VTE) is a well-known complication of the treatment of pediatric acute lymphoblastic leukemia (ALL). We analyzed 1026 ALL patients 1-18-years-old, who were enrolled into the AIEOP-BFM ALL 2000 or 2009 studies in Austria, with regard to the incidence and risk factors of VTE. The 2.5-year cumulative incidence (CI) of VTE ≥ grade 2 was 4%±1% (n = 36/1026). Twenty VTE (56%) were found in the central nervous system (19 cerebral venous sinus and 1 cortical vein thrombosis), and 16 (44%) at other sites (7 deep vein thromboses (DVT) of the lower extremity, 4 DVT of the upper extremity, 4 central venous line-thromboses, 1 pulmonary embolism). Most VTE occurred during induction and early consolidation therapy (81%) and were associated with L-asparaginase within 4 and corticosteroids withing 1 week(s) preceding the event (89 and 86%, respectively). In multivariable analysis, two independent risk factors were found. Patients 10-18-years-old had an increased (hazard-ratio: 2.156, p = 0.0389), whereas treatments in trial AIEOP-BFM ALL 2009 had a lower risk for VTE (hazard-ratio: 0.349, p = 0.0270). In conclusion, the 2.5-year CI of VTE among our pediatric patient cohort was <5% and adolescent age was the main patient-related risk factor. This older age group might benefit from primary prophylactic measures.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":"40 2","pages":"181-191"},"PeriodicalIF":1.7,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10711168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IL-10 and TNFα are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report. IL-10和TNFα与低风险小儿急性髓性白血病存活率下降有关；儿童肿瘤学小组报告。

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-03-01 Epub Date: 2022-07-15 DOI: 10.1080/08880018.2022.2089790

Alexandra M Stevens, Terzah M Horton, Chana L Glasser, Robert B Gerbing, Richard Aplenc, Todd A Alonzo, Michele S Redell

{"title":"IL-10 and TNFα are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report.","authors":"Alexandra M Stevens, Terzah M Horton, Chana L Glasser, Robert B Gerbing, Richard Aplenc, Todd A Alonzo, Michele S Redell","doi":"10.1080/08880018.2022.2089790","DOIUrl":"10.1080/08880018.2022.2089790","url":null,"abstract":"Pediatric acute myeloid leukemia (AML) is a devastating disease with a high risk of relapse. Current risk classification designates patients as high or low risk (LR) based on molecular features and therapy response. However, 30% of LR patients still suffer relapse, indicating a need for improvement in risk stratification. Cytokine levels, such as IL-6 and IL-10, have been shown to be prognostic in adult AML but have not been well studied in children. Previously, we reported elevated IL-6 levels in pediatric AML bone marrow to be associated with inferior prognosis. Here, we expanded our investigation to assess cytokine levels in diagnostic peripheral blood plasma (PBP) of pediatric AML patients and determined correlation with outcome. Diagnostic PBP was obtained from 80 patients with LR AML enrolled on the Children's Oncology Group AAML1031 study and normal PBP from 11 controls. Cytokine levels were measured and correlation with clinical outcome was assessed. IL-6, TNFα, MIP-3a, and IL-1β were significantly higher in AML patients versus controls when corrected by the Bonferroni method. Furthermore, elevated TNFα and IL-10 were significantly associated with inferior outcomes. Our data demonstrate that in diagnostic PBP of LR pediatric AML patients, certain cytokine levels are elevated as compared to healthy controls and that elevated TNFα and IL-10 are associated with inferior outcomes, supporting the idea that an abnormal inflammatory state may predict poor outcomes. Studies are needed to determine the mechanisms by which these cytokines impact survival, and to further evaluate their use as prognostic biomarkers in pediatric AML.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":"40 2","pages":"147-158"},"PeriodicalIF":1.7,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10232663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transient abnormal myelopoiesis in Down syndrome: Experience of long term follow up from a single tertiary center in Thailand. 唐氏综合征的短暂性骨髓异常:泰国单一三级中心的长期随访经验。

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-03-01 DOI: 10.1080/08880018.2022.2075501

Thirachit Chotsampancharoen, Shevachut Chavananon, Pornpun Sripornsawan, Natsaruth Songthawee, Edward B McNeil

引用次数: 2

How to recognize inborn errors of immunity in a child presenting with a malignancy: guidelines for the pediatric hemato-oncologist. 如何识别患恶性肿瘤儿童的先天性免疫错误：儿科血液肿瘤专家指南。

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-03-01 Epub Date: 2022-08-01 DOI: 10.1080/08880018.2022.2085830

Jutte van der Werff Ten Bosch, Eva Hlaváčková, Charlotte Derpoorter, Ute Fischer, Francesco Saettini, Sujal Ghosh, Roula Farah, Delfien Bogaert, Rabea Wagener, Jan Loeffen, Chris M Bacon, Simon Bomken

引用次数: 0

Internal evaluation of risk stratification tool using serial procalcitonin and clinical risk factors in pediatric febrile neutropenia: The non-interventional, single institution experience prior to clinical implementation. 使用系列降钙素原和临床危险因素对儿童发热性中性粒细胞减少症进行风险分层工具的内部评估:临床实施前的非介入性、单一机构经验。

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-03-01 DOI: 10.1080/08880018.2022.2079785

C N Nessle, T Braun, S W Choi, R Mody

{"title":"Internal evaluation of risk stratification tool using serial procalcitonin and clinical risk factors in pediatric febrile neutropenia: The non-interventional, single institution experience prior to clinical implementation.","authors":"C N Nessle, T Braun, S W Choi, R Mody","doi":"10.1080/08880018.2022.2079785","DOIUrl":"https://doi.org/10.1080/08880018.2022.2079785","url":null,"abstract":"Risk stratification of pediatric febrile neutropenia (FN) is an established concept, yet clinical risk tools misclassify nearly 5% of clinical standard-risk episodes with severe outcomes. The internal evaluation of a clinical risk tool before implementation has not been well-described. In this noninterventional cohort study, we evaluated a study decision rules (SDR) tool; a clinical risk tool with serial procalcitonin. The study standard-risk (SSR) group met clinical standard-risk criteria with two serial procalcitonin <0.4 ng/mL. The study high-risk (SHR) group met clinical high-risk criteria or clinical standard-risk with a procalcitonin ≥0.4 ng/mL. Descriptive and bivariate statistics compared the groups and outcomes. Clinical criteria alone identified 39.1% (238/608) standard-risk episodes; 5.9% (14/238) had severe events. Prospectively using the SDR, the SHR group encompassed 76.6% (92/120) of episodes; severe events occurred in 20% (3/15) of standard-risk episodes included due to elevated procalcitonin ≥0.4 ng/mL. The SHR group had more blood stream infections [21.7% (20/92) vs. 0% (0/28); P = 0.007] and intensive care admissions [13% (12/92) vs. 3.6% (1/28); P = 0.158]. In conclusion, the SDR with serial procalcitonin aided in identifying severe events in clinical standard-risk episodes, but analysis was limited. Institutions may consider similar internal evaluation methodology before FN episode risk stratification.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":"40 2","pages":"172-180"},"PeriodicalIF":1.7,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840714/pdf/nihms-1838145.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10814269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Impact of restrictive measures due to the Covid-19 pandemic on the incidence of immune thrombocytopenia in children: an Italian single center experience. Covid-19大流行导致的限制性措施对儿童免疫性血小板减少症发病率的影响:意大利单一中心的经验

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-03-01 DOI: 10.1080/08880018.2022.2095473

Giulia Ceglie, Antonio Musolino, Vitangelo Clemente, Silvio Marchesani, Francesca de Gennaro, Valeria Paganelli, Giuseppe Palumbo

引用次数: 1

Chlorhexidine gluconate (CHG) foam improves adherence, satisfaction, and maintains central line associated infection rates compared to CHG wipes in pediatric hematology-oncology and bone marrow transplant patients. 与CHG湿巾相比，在儿童血液肿瘤学和骨髓移植患者中，葡萄糖酸氯己定(CHG)泡沫提高了依从性、满意度，并维持了中央静脉相关感染率。

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-03-01 DOI: 10.1080/08880018.2022.2090644

Zachary D Prudowsky, Kandice Bledsaw, Sharon Staton, Mark Zobeck, Janet DeJean, Lindsay Johnson-Bishop, Anil George, David Steffin, Alexandra Stevens

{"title":"Chlorhexidine gluconate (CHG) foam improves adherence, satisfaction, and maintains central line associated infection rates compared to CHG wipes in pediatric hematology-oncology and bone marrow transplant patients.","authors":"Zachary D Prudowsky, Kandice Bledsaw, Sharon Staton, Mark Zobeck, Janet DeJean, Lindsay Johnson-Bishop, Anil George, David Steffin, Alexandra Stevens","doi":"10.1080/08880018.2022.2090644","DOIUrl":"https://doi.org/10.1080/08880018.2022.2090644","url":null,"abstract":"CHG-based hygiene methods are often a component of daily hygiene bundles to prevent central line-associated blood stream infections (CLABSIs) in pediatric hematology-oncology patients; however, adherence with 2% CHG wipes was inconsistent within our institution, risking infection for immunocompromised patients. A new 4% CHG foam method offers an alternative and is applied while bathing, as opposed to wipes used 1 h after bathing. An initial cohort of 24 high-risk oncology and bone marrow transplant (BMT) patients agreed to use 4% CHG foam in place of wipes, and then answered surveys to describe their experiences. Ninety-two percent preferred foam over wipes and were more likely to use the foam moving forward. CHG foam was then made available as an option to all patients in need of central line care upon admission to the hospital. Hygiene bundles in the electronic medical record were reviewed to measure baseline adherence rates. Random audits by nursing administration prospectively assessed CHG adherence. CLABSI data were collected prospectively with routine quality metric reports. Results were analyzed using run charts and u-charts, respectively. Hematology-Oncology unit adherence rates remained at a higher rate of adherence, and BMT unit adherence rates increased from an average of 55%-81.6% (p < 0.001). Primary CLABSIs remained rare events (average <1/1000 CVL days). On cost analysis, utilizing CHG foam results in an annual savings estimate of $40,000 for a 24-bed unit. In conclusion, 4% CHG foam provides a cost-effective and patient-preferred option for daily hygiene that maintains CLABSI preventative efforts.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":"40 2","pages":"159-171"},"PeriodicalIF":1.7,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9208407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Early mortality continues to be a barrier to excellent survival in childhood acute promyelocytic leukemia: a retrospective study of 62 patients spanning 17 years. 早期死亡仍然是儿童急性早幼粒细胞白血病良好生存率的障碍:一项对62例患者的回顾性研究，时间跨度为17年。

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-03-01 DOI: 10.1080/08880018.2022.2082610

Pritam Singha Roy, Vinay Munikoty, Amita Trehan, Richa Jain, Prateek Bhatia, Shano Naseem, Neelam Varma, Deepak Bansal

{"title":"Early mortality continues to be a barrier to excellent survival in childhood acute promyelocytic leukemia: a retrospective study of 62 patients spanning 17 years.","authors":"Pritam Singha Roy, Vinay Munikoty, Amita Trehan, Richa Jain, Prateek Bhatia, Shano Naseem, Neelam Varma, Deepak Bansal","doi":"10.1080/08880018.2022.2082610","DOIUrl":"https://doi.org/10.1080/08880018.2022.2082610","url":null,"abstract":"Data on childhood acute promyelocytic leukemia (APL) from low-and middle-income countries is limited. Early mortality is a concern and often not highlighted in clinical trials. The retrospective study was conducted on patients (≤12 years) with APL from 2003 to 2021 at a single center in India. Patients were treated with all-trans-retinoic acid (ATRA) and chemotherapy. Induction and three courses of consolidation were followed by maintenance for 2 years. In 2015, the protocol was updated with following modifications: (a) obtaining diagnostic cerebrospinal fluid at end-of-induction rather than at diagnosis, (b) administering intrathecal cytarabine regardless of risk-category, (c) risk-stratified administration of chemotherapy, and (d) inclusion of ATRA in all the cycles of consolidation. Sixty-two patients were diagnosed over the 17 years. The median age was 8 years (range: 0.9-12). Half had high-risk disease. Differentiation syndrome was observed in 32%, none being fatal. Eighteen (29%) patients died due to hemorrhage (83%) or septicemia (17%). Thirteen (21%) had early mortality (≤15 days), all due to hemorrhage. A platelet count <20 × 109/L predicted early mortality (odds ratio: 4.5; 95% CI: 0.9-22, p = 0.06). Treatment abandonment reduced from 23.5% during 2003-2015 to nil during 2015-2021 (p = 0.006). Three (8%) patients relapsed. The 4-year OS of all patients and the patients who survived >15 days was 70.1% and 89.6%, respectively. The 4-year EFS, including abandonment and early mortality, before and following updated protocol, was 61.4% and 65.5%, respectively (p = 0.77). Early mortality continues to be a barrier to an otherwise excellent survival in childhood APL. A significant reduction in treatment abandonment in recent years is gratifying.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":"40 2","pages":"117-130"},"PeriodicalIF":1.7,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10711165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-02-01 DOI: 10.1080/08880018.2022.2069895

Revathi Rajagopal, Nur'Aini Raman, Lai Choo Ong, Jen Chun Foo, Choong Yi Fong

{"title":"Health-related quality of life among Malaysian pediatric survivors of central nervous system tumor.","authors":"Revathi Rajagopal, Nur'Aini Raman, Lai Choo Ong, Jen Chun Foo, Choong Yi Fong","doi":"10.1080/08880018.2022.2069895","DOIUrl":"https://doi.org/10.1080/08880018.2022.2069895","url":null,"abstract":"Pediatric central nervous system tumor survivors (CNSTS) experience late effects that may affect their health-related quality of life (HRQOL). The study aims: i) compare HRQOL among Malaysian CNSTS with acute lymphoblastic leukemia survivors (ALLS) and healthy children, and ii) explore factors associated with low HRQOL. We performed a comparative cross-sectional HRQOL study of 46 CNSTS aged 5-18 years and 90 ALLS (age and gender-matched) who completed treatment for >1 year, and a published cohort of healthy children. Pediatric Quality of Life Inventory (PedsQL) was used for all groups and PedsQL Cancer Module for CNSTS and ALLS. Multiple regression analysis was used to determine factors associated with low HRQOL. Mean PedsQL total scale score, physical health score and psychosocial health score of CNSTS were 69.0 (SD 20.3), 68.7 (SD 27.9) and 69.2 (SD 19.2) respectively. These scores were significantly lower in all domains particularly in teenagers compared with healthy children and ALLS. The median PedsQL Cancer Module score of CNSTS was significantly lower than ALLS in total scale, cognitive problems and communication. Physical impairment was associated with lower PedsQL scores in all 3 domains; special education placement was associated with lower PedsQL total scale and physical health scores and clinically significant internalizing behavioral difficulties score was associated with lower PedsQL psychosocial health scores. CNSTS reported lower PedsQL scores in all domains than ALLS and healthy children. Clinicians need to be vigilant of HRQOL needs among CNSTS, especially those with risk factors of special education needs, physical impairment, and internalizing behavioral difficulties.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":"40 1","pages":"26-39"},"PeriodicalIF":1.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10588929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1